1. Home
  2. WEAV vs NMRA Comparison

WEAV vs NMRA Comparison

Compare WEAV & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weave Communications Inc.

WEAV

Weave Communications Inc.

HOLD

Current Price

$6.84

Market Cap

524.3M

Sector

Technology

ML Signal

HOLD

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$2.07

Market Cap

424.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEAV
NMRA
Founded
2011
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
524.3M
424.4M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
WEAV
NMRA
Price
$6.84
$2.07
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$12.20
$8.00
AVG Volume (30 Days)
1.4M
2.4M
Earning Date
02-19-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$229,790,000.00
N/A
Revenue This Year
$19.22
N/A
Revenue Next Year
$15.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.34
N/A
52 Week Low
$5.64
$0.61
52 Week High
$17.63
$3.25

Technical Indicators

Market Signals
Indicator
WEAV
NMRA
Relative Strength Index (RSI) 48.06 51.81
Support Level $6.48 $1.84
Resistance Level $7.32 $2.18
Average True Range (ATR) 0.30 0.24
MACD -0.06 0.01
Stochastic Oscillator 30.20 53.74

Price Performance

Historical Comparison
WEAV
NMRA

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: